BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 13852382)

  • 1. The action of chelating agents in Wilson's disease.
    HILL L; WALSHE JM
    Lancet; 1959 Sep; 2(7100):444-5. PubMed ID: 13852382
    [No Abstract]   [Full Text] [Related]  

  • 2. Chelating agents in the treatment of hepatolenticular degeneration (Wilson's disease).
    BLATTNER RJ
    J Pediatr; 1958 Jun; 52(6):758-61. PubMed ID: 13550045
    [No Abstract]   [Full Text] [Related]  

  • 3. [Metabolism of iron and copper, action of chelators and therapeutic possibilities in Wilson's disease and hemochromatosis].
    PIRART J
    Pathol Biol; 1961 May; 9():1157-74. PubMed ID: 13735975
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of hepatolenticular degeneration (Wilson's disease).
    Traugh G
    Arch Phys Med Rehabil; 1971 Mar; 52(3):126-9. PubMed ID: 5575151
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of chronic Wilson's disease in 2 patients using plasmapheresis--clinico-biochemical observations].
    Milovanović DD; Tomasević R; Bogdanović G
    Srp Arh Celok Lek; 1998; 126(9-10):327-34. PubMed ID: 9863403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Wilson's disease].
    Propst T; Propst A; Judmaier G; Vogel W
    Dtsch Med Wochenschr; 1996 Mar; 121(9):280-4. PubMed ID: 8681776
    [No Abstract]   [Full Text] [Related]  

  • 7. Wilson's disease: from the liver to the brain.
    Taylor R; Dhawan A
    Nurs Times; 2001 Jul 26-Aug 1; 97(30):38-40. PubMed ID: 11957950
    [No Abstract]   [Full Text] [Related]  

  • 8. [DO CHELATING AGENTS CURE WILSON'S DISEASE?].
    BOUDIN G; PEPIN B; CAMBIER J; LAPRESLE J; LEBEAU J; PEQUIGNOT H
    Presse Med (1893); 1965 Apr; 73():1047-9. PubMed ID: 14264484
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of Wilson's disease.
    Jabłońska-Kaszewska I; Dabrowska E; Drobińska Jurowiecka A; Falkiewicz B
    Med Sci Monit; 2003 Aug; 9 Suppl 3():5-8. PubMed ID: 15156602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [WILSON'S DISEASE].
    WATANABE H
    Naika; 1965 Mar; 15():435-8. PubMed ID: 14323829
    [No Abstract]   [Full Text] [Related]  

  • 11. The bane of a silent illness: when Wilson's disease takes its course.
    Chahine LM; Chemali ZN
    Int J Psychiatry Med; 2006; 36(3):333-8. PubMed ID: 17236700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anesthesia for a patient with Wilson's disease--a case report.
    De Souza Hobaika AB
    Middle East J Anaesthesiol; 2008 Feb; 19(4):905-8. PubMed ID: 18630776
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathophysiology and treatment of Wilson's disease.
    Tankanow RM
    Clin Pharm; 1991 Nov; 10(11):839-49. PubMed ID: 1794220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Membranoproliferative glomerulonephritis in a patient with Wilson's disease.
    Ozçakar ZB; Ekim M; Ensari A; Kuloglu Z; Yüksel S; Acar B; Kirsaçlioglu C; Kansu A; Yalçinkaya F; Girgin N
    J Nephrol; 2006; 19(6):831-3. PubMed ID: 17173260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHELATING AGENTS IN WILSON'S DISEASE.
    SELZER G
    Lancet; 1963 Aug; 2(7303):341-2. PubMed ID: 14044277
    [No Abstract]   [Full Text] [Related]  

  • 16. The long term management of hepatolenticular degeneration (Wilson's disease).
    SCHEINBERG IH; STERNLIEB I
    Am J Med; 1960 Aug; 29():316-33. PubMed ID: 13747430
    [No Abstract]   [Full Text] [Related]  

  • 17. Wilson's disease with severe hepatic insufficiency: beneficial effects of early administration of D-penicillamine.
    Durand F; Bernuau J; Giostra E; Mentha G; Shouval D; Degott C; Benhamou JP; Valla D
    Gut; 2001 Jun; 48(6):849-52. PubMed ID: 11358907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pure hepatic form of Wilson's disease in infant; successful therapy with chelating agents].
    FRANCOIS R; LARBRE F; NICOLAS ; MALLEIN ; RUITTON-UGLIENGO
    Lyon Med; 1958 Mar; 90(12):467-83. PubMed ID: 13540356
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of BAL (2,3-dimercaptopropanol) on hepatolenticular degeneration (Wilson's disease).
    DENNY-BROWN D; PORTER H
    Trans Am Neurol Assoc; 1951; 56():79-84. PubMed ID: 14913592
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of BAL (2,3-dimercaptopropanol) on hepatolenticular degeneration (Wilson's disease).
    DENNY-BROWN D; PORTER H
    N Engl J Med; 1951 Dec; 245(24):917-25. PubMed ID: 14882450
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.